Astellas To Pay $13.3M To Settle Prograf Antitrust Case
Astellas Pharma agreed Thursday to pay indirect purchasers of its Prograf $13.25 million to settle claims that it delayed generic competition to the immunosuppressant drug amid an appeal of class certification...To view the full article, register now.
Already a subscriber? Click here to view full article